The authors have withdrawn this manuscript because they identified problems with how some figure panels were processed. Those experiments will be repeated before deposition of a new manuscript. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding authors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11429910 | PMC |
| http://dx.doi.org/10.1101/2024.09.17.613558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The authors have withdrawn this manuscript because they identified problems with how some figure panels were processed. Those experiments will be repeated before deposition of a new manuscript. Therefore, the authors do not wish this work to be cited as reference for the project.
View Article and Find Full Text PDFSocial withdrawal behaviour in Nepalese infants and the relationship with future neurodevelopment; a longitudinal cohort study.
BMC Pediatr
March 2024
Department of Research, Innlandet Hospital Trust, Lillehammer, Norway.
Background: Social withdrawal in infants may be a signal of distress and a precursor for non-optimal development.
Objective: To examine the relationship between infant social withdrawal and neurodevelopment up to 4 years in Nepalese children.
Methods: A total of 597 Nepalese infants 6-11 months old were assessed with the modified Alarm Distress Baby Scale (m-ADBB), and of these, 527 with the Bayley Scales of Infant and Toddler Development 3rd edition (Bayley-III) during early childhood, and the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) and NEPSY-II subtests at 4 years.
[Toward the complete understanding of the pathogenic mechanism of clioquinol-induced subacute myelo-optic neuropathy (SMON)].
Nihon Yakurigaku Zasshi
March 2024
Radioisotope Center, Kyoto Prefectural University of Medicine.
Clioquinol was extensively used as an amebicide to treat indigestion and diarrhea in the mid-1900s. However, it was withdrawn from the market in Japan because its use was epidemiologically linked to an increase in the incidence of subacute myelo-optic neuropathy (SMON). SMON is characterized by the subacute onset of sensory and motor disturbances in the lower extremities with occasional visual impairments, which are preceded by abdominal symptoms.
View Article and Find Full Text PDFSuccessful glucocorticoid withdrawal in Chinese lupus nephritis patients: A single centre experience.
Int Immunopharmacol
December 2023
Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Beijing, China; Key laboratory of Renal Disease, Ministry of Health of China; Key laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China; Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing 100034, PR China.
Objective: To evaluate the proportion of patients successfully withdrawn from glucocorticoids (GC) in a longitudinal cohort of patients with lupus nephritis over a period of 20 years, clinical and pathological predictors of patients with GC withdrawal and renal outcomes after GC withdrawal were further explored.
Methods: Patients with successful GC withdrawal were identified for the cohort, and the following data were collected: demographic characteristics, clinical manifestations, pathological findings at disease onset, flares, and renal outcomes subsequent to GC withdrawal.
Results: There were 365 patients with lupus nephritis included with a median follow-up of 109.
Efficacy of belimumab for severe childhood-onset systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A case report.
Medicine (Baltimore)
August 2023
Department of Nephrology, People's Hospital of Guizhou Province, Guiyang, China.
Article Synopsis
- Therapy for childhood systemic lupus erythematosus (cSLE) is often ineffective, but new drugs like belimumab and rituximab show promise, especially for severe cases.
- A case study of a 16-year-old girl with severe cSLE demonstrated limited success with traditional treatments, but she experienced significant improvement after being treated with belimumab, which she tolerated well.
- The findings suggest that belimumab could be an effective treatment option for severe cSLE in children who do not respond to standard therapies, potentially leading to rapid improvement and fewer side effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!